GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » SillaJen Inc (XKRX:215600) » Definitions » Institutional Ownership

SillaJen (XKRX:215600) Institutional Ownership : 0.43% (As of May. 06, 2025)


View and export this data going back to 2016. Start your Free Trial

What is SillaJen Institutional Ownership?

Institutional ownership is the percentage of shares that are owned by institutions out of the total shares outstanding. As of today, SillaJen's institutional ownership is 0.43%.

Insider Ownership is the percentage of shares that are owned by company insiders relative to the total shares outstanding. As of today, SillaJen's Insider Ownership is 0.00%.

Float Percentage Of Total Shares Outstanding is the percentage of float shares relative to the total shares outstanding. As of today, SillaJen's Float Percentage Of Total Shares Outstanding is 0.00%.


SillaJen Institutional Ownership Historical Data

The historical data trend for SillaJen's Institutional Ownership can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

SillaJen Institutional Ownership Chart

SillaJen Historical Data

The historical data trend for SillaJen can be seen below:

2024-07-31 2024-08-31 2024-09-30 2024-10-31 2024-11-30 2024-12-31 2025-01-31 2025-02-28 2025-03-31 2025-04-30
Institutional Ownership 2.49 2.62 2.93 2.86 3.27 0.47 0.46 0.44 0.44 0.43

SillaJen Institutional Ownership Calculation

The percentage of shares that are owned by institutions out of the total shares outstanding.


SillaJen Business Description

Traded in Other Exchanges
N/A
Address
6F, 252, Geumjeong-ro, Geumjeong-gu, Busan, KOR, 46274
SillaJen Inc is a Korean based biotechnology company focused on engineering and developing cancer treatment cells. The company along with its subsidiary SillaJen Biotherapeutics, Inc offers Pexa-Vec, an oncolytic virus with antibodies, and improved survival in a randomized trial to cure cancer; and JX929, an engineered vaccinia virus strain that acts on cancer cells by viral attack and subsequent cancer cell oncolysis. SillaJen operates its business activities in Korea and United States.

SillaJen Headlines

No Headlines